

HHS Issues Final Rule on Medications for the Treatment of Opioid Use Disorder

- Substance Abuse and Mental Health Services Administration (SAMHSA) within the Department of Health and Human Services (“HHS”) issued a final rule on Medications for the Treatment of Opioid Use Disorder (Final Rule), to be published on Feb. 2, 2024.
- The Final Rule updates regulations related to Opioid Treatment Program (OTP) accreditation, certification, and standards for the treatment of Opioid Use Disorder (OUD) with Medications for Opioid Use Disorder (MOUD) in OTPs. The Final Rule also updates requirements for individual practitioners to dispense and prescribe certain types of MOUD with a waiver.
- In March 2020, SAMHSA published guidance regarding COVID-19 flexibilities that could be leveraged in the provision of unsupervised doses of methadone and the use of telehealth when initiating buprenorphine. This Final Rule makes these COVID-19 flexibilities permanent and updates standards to reflect an evolving accreditation and treatment environment.
- Effective date - April 2, 2024; compliance date - April 2, 2026.

More on This Topic:

- [Final Rule](#)

For questions, please reach out to [Vicky Jucelin](#).

AMCP | 675 North Washington Street, Suite 220 | Alexandria,VA,22314

[Manage Preferences](#)

